[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353957-105":59,"doc-detail-353957-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","epigenetic-editing-to-advance-cart-cell-therapy-review","Epigenetic editing to advance CART cell therapy - Review","","Chimeric antigen receptor (CAR) T cell therapy enables selective targeting of tumor cells and has transformed treatment of hematologic cancers, yet 40–60% of patients fail to achieve durable responses. In solid tumors, poor infiltration and immunosuppressive tumor microenvironments limit clinical translation. T cell–intrinsic differentiation into short-lived effectors and progressive exhaustion undermine persistence. Epigenetic regulation controls activation, memory, and exhaustion, and targeted gene epigenetic editing can reprogram CAR T phenotypes by reversible, DNA-break-free modulation of inhibitory pathways.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/epigenetic-editing-to-advance-cart-cell-therapy-review/353957/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/epigenetic-editing-to-advance-cart-cell-therapy-review/353957.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why does CAR T therapy often fail to produce durable responses?","Question",{"text":113,"@type":114},"Many patients do not reach durable response, with T cell–intrinsic programs driving differentiation into short-lived effector cells and progressive exhaustion. These processes reduce CAR T persistence and therapeutic efficacy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do epigenetic modifications influence CAR T cell behavior?",{"text":118,"@type":114},"Epigenetic modifications regulate T cell activation, memory formation, and exhaustion. By shaping these programs, they critically determine CAR T persistence and clinical effectiveness.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the rationale behind gene-targeted epigenetic editing for CAR T cells?",{"text":122,"@type":114},"Gene-targeted epigenetic editing enables precise, durable, and reversible reprogramming of gene expression without introducing DNA breaks. Proof-of-concept studies show targeted silencing of inhibitory receptors such as PD-1 and LAG-3 to shape CAR T phenotypes safely.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353957,1790147974,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Horvathova et al. Clinical Epigenetics (2026) 18:50  \n[https://doi.org/10.1186/s13148-026-02085-1](https://doi.org/10.1186/s13148-026-02085-1)  \nClinical Epigenetics  \nREVIEW Open Access  \nEpigenetic editing to advance CART cell therapy  \nLaura Horvathova 1, Marianne G. Rots 1 and Valerie R. Wiersma2*  \nAbstract  \nChimeric antigen receptor (CAR) T cell therapy has revolutionized cancer treatment by enabling the selective targeting and elimination of tumor cells. Although CAR T therapy offers a potential cure for haematological cancers, 40–60% of patients do not reach a durable response. In solid tumors, limited infiltration and the immunosuppressive tumor microenvironment have so far hindered clinical translation. Central to these challenges are T cell–intrinsic programs, including differentiation into short-lived effector cells and progressive exhaustion. Epigenetic modifications regulate T cell activation, memory formation, and exhaustion, thereby critically shaping CAR T cell persistence and therapeutic efficacy. Early studies have demonstrated that disrupting or inhibiting key epigenetic regulators such as ten-eleven translocation 2 (TET2) or DNA methyltransferase 3A (DNMT3A) can bias CAR T cells toward memory-like, non-exhausted states with superior antitumor activity. Building on these findings, gene-targeted epigenetic editing has recently emerged as a next-generation approach, offering precise, durable, and reversible reprogramming of gene expression without introducing DNA breaks. Proof-of-concept studies have demonstrated targeted and durable silencing of key inhibitory receptors such as programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) as a safe strategy to shape CAR T cell phenotypes. Beyond phenotype modulation, epigenetic editing also offers opportunities for off-the-shelf donor-derived CAR T cells by enabling stable silencing of immune rejection pathways, thereby addressing key barriers to their clinical application. This review highlights the pivotal role of epigenetic regulation in T cell biology and CAR T cell therapy, and explores how epigenetic drugs, genetic interventions, and emerging epigenetic editing strategies can be harnessed to generate more potent, persistent, and widely accessible CAR T cell therapies.  \nKeywords CRISPR, ZFP, TALE, Epigenetics, CAR-T  \n*Correspondence: Valerie R. Wiersma [v.wiersma@umcg.nl](v.wiersma@umcg.nl)  \n1Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 2Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands  \nIntroduction  \nThe development ofChimeric Antigen Receptor (CAR) T cell therapies marked a revolutionary advance in the field of oncology, particularly in the treatment of B cell malignancies [1, 2]. CAR T cells are genetically engineered to target and destroy cancer cells, offering a highly adaptable approach to cancer treatment [1, 3]. One of the major advantages of CAR T cells is their potential to provide sustained therapeutic effects long following administration, serving as \"living drugs\" [4]. CAR T cell manufacture is a stepwise process, typically involving T cell isolation from the leukapheresis product, followed by  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated other","cbCaivftOc1RasjV","https://ap.wps.com/l/cbCaivftOc1RasjV","pdf",1240995,11,"English","# Abstract\n# Introduction","[{\"question\":\"Why does CAR T therapy often fail to produce durable responses?\",\"answer\":\"Many patients do not reach durable response, with T cell–intrinsic programs driving differentiation into short-lived effector cells and progressive exhaustion. These processes reduce CAR T persistence and therapeutic efficacy.\"},{\"question\":\"How do epigenetic modifications influence CAR T cell behavior?\",\"answer\":\"Epigenetic modifications regulate T cell activation, memory formation, and exhaustion. By shaping these programs, they critically determine CAR T persistence and clinical effectiveness.\"},{\"question\":\"What is the rationale behind gene-targeted epigenetic editing for CAR T cells?\",\"answer\":\"Gene-targeted epigenetic editing enables precise, durable, and reversible reprogramming of gene expression without introducing DNA breaks. Proof-of-concept studies show targeted silencing of inhibitory receptors such as PD-1 and LAG-3 to shape CAR T phenotypes safely.\"}]","Epigenetic editing to advance CART cell therapy - Review | PDF",1790108111,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b63bd326652e8438d97ce92b0d30b18.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe30c256e5054fe1114cf9ce3f1ed64d.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3e68dfa669474966f4c04b0813858b9.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/845d5453d85e5894bc2ab7eb2b2be804.webp",980,1306]